Cantor Fitzgerald Forecasts Lower Earnings for Amgen

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Amgen in a research note issued to investors on Wednesday, February 5th. Cantor Fitzgerald analyst O. Brayer now forecasts that the medical research company will post earnings of $20.67 per share for the year, down from their previous forecast of $21.44. Cantor Fitzgerald currently has a “Overweight” rating and a $405.00 target price on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.56 per share.

Several other analysts have also recently commented on the company. Deutsche Bank Aktiengesellschaft lowered their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Citigroup cut their price objective on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Leerink Partners cut their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $314.83.

Amgen Stock Performance

Shares of AMGN opened at $297.78 on Thursday. The company has a market capitalization of $160.07 billion, a price-to-earnings ratio of 38.13, a PEG ratio of 2.87 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen has a 1 year low of $253.30 and a 1 year high of $346.85. The company’s 50 day simple moving average is $271.69 and its 200 day simple moving average is $303.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%.

Institutional Investors Weigh In On Amgen

A number of large investors have recently bought and sold shares of the business. Capital Performance Advisors LLP bought a new position in shares of Amgen in the third quarter valued at approximately $25,000. Centricity Wealth Management LLC acquired a new position in shares of Amgen during the fourth quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the third quarter valued at about $29,000. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the 4th quarter worth approximately $34,000. Finally, Matrix Trust Co acquired a new stake in Amgen during the third quarter worth $36,000. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.69% of the stock is currently owned by corporate insiders.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.20%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.